Results 11 to 20 of about 318,139 (404)

Fremanezumab for the Preventive Treatment of Chronic Migraine. [PDF]

New England Journal of Medicine, 2017
BACKGROUND: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine.
Aycardi, Ernesto, Bigal, Marcelo E., Blankenbiller, Tricia, Dodick, David W., Goadsby, Peter J., Grozinski-Wolff, Melissa, Ma, Yuju, Silberstein, Stephen D., Yang, Ronghua, Yeung, Paul P.   +9 more
core   +3 more sources

Chronic Migraine Pathophysiology and Treatment: A Review of Current Perspectives

Frontiers in Pain Research, 2021
Chronic migraine is a disabling neurological disorder that imposes a considerable burden on individual and socioeconomic outcomes. Chronic migraine is defined as headaches occurring on at least 15 days per month with at least eight of these fulfilling ...
Tiffani J. Mungoven, Luke A. Henderson, Noemi Meylakh   +2 more
doaj   +2 more sources

ON MIGRAINE. [PDF]

The Lancet, 1893
n ...
Alexander Wallace
  +6 more sources

Genetics of migraine: where are we now?

The Journal of Headache and Pain, 2023
Migraine is a complex brain disorder explained by the interaction of genetic and environmental factors. In monogenic migraines, including familial hemiplegic migraine and migraine with aura associated with hereditary small-vessel disorders, the ...
L. Grangeon, K. S. Lange, M. Waliszewska-Prosół, D. Onan, Karol Marschollek, Wietse A. Wiels, Petr Mikulenka, F. Farham, C. Gollion, A. Ducros   +9 more
semanticscholar   +1 more source

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

The Journal of Headache and Pain, 2022
Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world
S. Sacco, F. Amin, M. Ashina, L. Bendtsen, C. Deligianni, R. Gil‐Gouveia, Z. Katsarava, A. Maassenvandenbrink, P. Martelletti, D. Mitsikostas, R. Ornello, U. Reuter, M. Sanchez-del-Rio, A. Sinclair, G. Terwindt, D. Uluduz, J. Versijpt, C. Lampl   +17 more
semanticscholar   +1 more source

Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities

Frontiers in Neurology, 2022
Migraine affects more than one billion individuals each year across the world, and is one of the most common neurologic disorders, with a high prevalence and morbidity, especially among young adults and females.
P. Amiri, S. Kazeminasab, S. A. Nejadghaderi, R. Mohammadinasab, H. Pourfathi, Mostafa Araj-khodaei, M. Sullman, Ali-Asghar Kolahi, S. Safiri   +8 more
semanticscholar   +1 more source

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Headache, 2021
To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.
J. Ailani, R. Burch, M. Robbins
semanticscholar   +1 more source

Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles

Nature Genetics, 2021
Migraine affects over a billion individuals worldwide but its genetic underpinning remains largely unknown. Here, we performed a genome-wide association study of 102,084 migraine cases and 771,257 controls and identified 123 loci, of which 86 are ...
Heidi Hautakangas, B. Winsvold, S. Ruotsalainen, G. Bjornsdottir, A. V. Harder, Lisette J. A. Kogelman, Laurent F. Thomas, R. Noordam, C. Benner, P. Gormley, V. Artto, K. Banasik, A. Bjornsdottir, D. Boomsma, B. Brumpton, K. Burgdorf, J. Buring, M. A. Chalmer, I. de Boer, M. Dichgans, C. Erikstrup, M. Färkkilä, Maiken Elvestad Garbrielsen, M. Ghanbari, K. Hagen, Paavo Häppölä, J. Hottenga, M. Hrafnsdottir, K. Hveem, M. B. Johnsen, M. Kähönen, E. Kristoffersen, T. Kurth, T. Lehtimäki, Lannie Lighart, S. Magnusson, R. Malik, O. Pedersen, N. Pelzer, B. Penninx, C. Ran, P. Ridker, F. Rosendaal, Gudrun R. Sigurdardottir, A. Skogholt, O. Sveinsson, T. Thorgeirsson, H. Ullum, L. Vijfhuizen, E. Widén, K. W. van Dijk, Irene Arn M. J. M. de Boer van den Maagdenberg, I. de Boer, A. M. van den Maagdenberg, A. Aromaa, A. C. Belin, T. Freilinger, M. Ikram, M. Järvelin, O. Raitakari, G. Terwindt, M. Kallela, M. Wessman, Jes Olesen, D. Chasman, D. Nyholt, H. Stefánsson, K. Stefánsson, T. Hansen, S. Ripatti, J. Zwart, A. Palotie, M. Pirinen   +72 more
semanticscholar   +1 more source

Migraine [PDF]

New England Journal of Medicine, 2008
Abstract
openaire   +6 more sources

Circadian Variation of Migraine Attack Onset Affects fMRI Brain Response to Fearful Faces

Frontiers in Human Neuroscience, 2022
BackgroundPrevious studies suggested a circadian variation of migraine attack onset, although, with contradictory results – possibly because of the existence of migraine subgroups with different circadian attack onset peaks. Migraine is primarily a brain
Daniel Baksa, Daniel Baksa, Daniel Baksa, Edina Szabo, Edina Szabo, Edina Szabo, Natalia Kocsel, Natalia Kocsel, Attila Galambos, Attila Galambos, Andrea Edit Edes, Andrea Edit Edes, Dorottya Pap, Terezia Zsombok, Mate Magyar, Mate Magyar, Mate Magyar, Kinga Gecse, Kinga Gecse, Dora Dobos, Dora Dobos, Lajos Rudolf Kozak, Gyorgy Bagdy, Gyorgy Bagdy, Gyorgy Bagdy, Gyongyi Kokonyei, Gyongyi Kokonyei, Gyongyi Kokonyei, Gabriella Juhasz, Gabriella Juhasz, Gabriella Juhasz, Gabriella Juhasz   +31 more
doaj   +1 more source